Procoagulant platelets mediate cerebral arterial thrombosis in cancer
This study reveals that cancer-associated arterial thrombosis is driven by a distinct procoagulant platelet phenotype and neutrophil extracellular traps, resulting in platelet-rich thrombi that differ significantly from the red blood cell-rich clots found in non-cancer stroke patients.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer is a disease that changes how the body functions, often making the blood more prone to clotting. When a blood clot forms inside a brain artery, it causes an ischemic stroke, a sudden blockage that cuts off oxygen to brain tissue. For decades, doctors have known that people with cancer face a higher risk of these strokes, but the exact reason why has remained a mystery. It was unclear whether the cancer simply made the blood stickier everywhere in the body, or if something more specific happened at the exact spot where the clot formed. Understanding this difference is crucial because the treatment for a standard stroke might not work if the clot in a cancer patient is built from different materials.
A team of researchers from Italy set out to solve this puzzle by looking directly at the clots themselves. They gathered blood samples and, in many cases, the actual clots removed from the brains of patients who had just suffered a stroke. They divided these patients into three groups: those with a stroke and cancer, those with a stroke but no cancer, and those with cancer but no stroke. By comparing these groups, the scientists could see what was unique about the clots formed in the presence of cancer.
The researchers first looked at the blood circulating in the veins of these patients. They checked for signs of inflammation, markers of blood vessel damage, and various proteins that help blood clot. Surprisingly, they found very few differences between the groups. The blood of a cancer patient with a stroke looked much like the blood of a cancer patient without a stroke, or a stroke patient without cancer. This suggested that the danger was not coming from a general, body-wide change in the blood. The clues were not in the river, but in the dam.
To find the real story, the team examined the clots that had been physically removed from the patients' brain arteries during surgery. When they looked at these clots under a microscope, a stark difference appeared. The clots from patients without cancer were mostly made of red blood cells, packed tightly together like a dense red mass. In contrast, the clots from patients with cancer were dominated by platelets, the tiny cells that act as the body's first responders to bleeding. These cancer-associated clots were white and platelet-rich, and they contained a complex network of fibers and trapped immune cells that were largely absent in the other group.
Inside these cancer-related clots, the researchers found a specific type of platelet that behaves differently. These platelets had undergone a dramatic transformation, swelling up and changing their shape into a balloon-like form. This change is a sign that the platelet has become a "procoagulant" cell, meaning it is actively working to solidify the clot and make it very hard to break apart. These swollen platelets were not just floating around; they were tightly interwoven with neutrophils, a type of white blood cell that fights infection. The neutrophils had released a web of DNA fibers, known as a trap, which the platelets used as a scaffold to build a stronger, more stable clot.
To test if this was caused by something in the blood, the scientists took platelets from healthy volunteers and mixed them with blood plasma from the different patient groups. When they added plasma from the cancer patients, the healthy platelets began to swell and change shape, mimicking the behavior seen in the actual brain clots. This proved that the cancer patients' blood contained specific signals that could reprogram platelets to become these aggressive, clot-building cells, even before a stroke occurred.
The study suggests that the risk of stroke in cancer patients is not due to a general increase in blood stickiness, but rather to a specific, localized event. The cancer seems to send signals that prime the platelets to become hyper-aggressive. When a clot starts to form in the brain, these primed platelets rapidly transform, creating a dense, platelet-rich structure that is reinforced by immune cells. This makes the clot particularly stubborn and difficult to treat. The findings point toward a new way of thinking about treatment: instead of just trying to thin the blood, future therapies might need to target these specific platelet transformations or the immune cells that help build the clot, offering a more precise way to protect cancer patients from the devastating effects of stroke.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.